Advertisement
Screener

Arbutus Biopharma Corp (ABUS) Segment Reporting Other Item Amount

2.8 / 5 stars · 68/120 Roast Me

Arbutus Biopharma Corp Segment Reporting Other Item Amount

Arbutus Biopharma Corp (ABUS) reported Segment Reporting Other Item Amount of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Notes › Segment Reporting

us-gaap:SegmentReportingOtherItemAmount · last filed 2026-08-12

  • Arbutus Biopharma Corp segment reporting other item amount for the quarter ending 2026-06-30 was $0.00.
  • Arbutus Biopharma Corp segment reporting other item amount for the quarter ending 2026-03-31 was $0.00.
  • Arbutus Biopharma Corp segment reporting other item amount for the quarter ending 2025-12-31 was $0.00.
  • Arbutus Biopharma Corp segment reporting other item amount for the quarter ending 2025-09-30 was $0.00.
  • Arbutus Biopharma Corp segment reporting other item amount for fiscal 2025 was $0.00.
  • Arbutus Biopharma Corp segment reporting other item amount for fiscal 2024 was $0.00.
  • Arbutus Biopharma Corp segment reporting other item amount for fiscal 2023 was $0.00.
Period endSegment Reporting Other Item Amount 3 monthSegment Reporting Other Item Amount 6 monthSegment Reporting Other Item Amount 9 monthSegment Reporting Other Item Amount 12 month
2026-06-30$0.00
10-Q · filed 2026-08-12
$0.00
10-Q · filed 2026-08-12
$0.00
derived: sum of 3 quarters · filed 2026-08-12
$0.00
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31$0.00
10-Q · filed 2026-05-13
$0.00
derived: sum of 2 quarters · filed 2026-05-13
$0.00
derived: sum of 3 quarters · filed 2026-05-13
$0.00
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23
$0.00
derived: sum of 2 quarters · filed 2026-03-23
$0.00
derived: sum of 3 quarters · filed 2026-08-12
$0.00
10-K · filed 2026-03-23
2025-09-30$0.00
10-Q · filed 2025-11-13
$0.00
derived: sum of 2 quarters · filed 2026-08-12
$0.00
10-Q · filed 2025-11-13
$0.00
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30$0.00
10-Q · filed 2026-08-12
$0.00
10-Q · filed 2026-08-12
$0.00
derived: sum of 3 quarters · filed 2026-08-12
$0.00
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31$0.00
10-Q · filed 2026-05-13
$0.00
derived: sum of 2 quarters · filed 2026-05-13
$0.00
derived: sum of 3 quarters · filed 2026-05-13
$0.00
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23
$0.00
derived: sum of 2 quarters · filed 2026-03-23
$0.00
derived: sum of 3 quarters · filed 2026-03-23
$0.00
10-K · filed 2026-03-23
2024-09-30$0.00
10-Q · filed 2025-11-13
$0.00
derived: sum of 2 quarters · filed 2025-11-13
$0.00
10-Q · filed 2025-11-13
2024-06-30$0.00
10-Q · filed 2025-08-06
$0.00
10-Q · filed 2025-08-06
2024-03-31$0.00
10-Q · filed 2025-05-14
2023-12-31$0.00
10-K · filed 2025-03-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Apnimed, Inc. (APMD)United States$0.899B
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
RIGEL PHARMACEUTICALS INC (RIGL)United States$0.893B2.25
Savara Inc (SVRA)United States$1.044B-9.10
Theravance Biopharma, Inc. (TBPH)$0.885B16.40